Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
RESEARCH TOOLSreports
Holding CRBU?
Track your performance easily
CRBU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.50 - $8.33
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.50M
Market Cap
$141.26M
Enterprise Value-$24.23M
Total Cash (Recent Filing)$49.47M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Mar 24, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding90,552,690
10 Day Avg. Volume1,673,770
30 Day Avg. Volume1,500,607
Standard Deviation0.28
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.39
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.17
Enterprise Value/Revenue-2.11
Enterprise Value/Gross Profit-0.70
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$12.43Price Target Upside707.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Caribou Biosciences News
PremiumCompany Announcements
Caribou Biosciences Advances CAR-T Therapy Trials
PremiumCompany Announcements
Caribou Biosciences Appoints New CFO Amid Clinical Advancements
Bulls Say, Bears Say
Bulls Say
Cost ManagementR&D and SG&A expenses were below consensus estimates, indicating effective cost management.
Financial StabilityCaribou ended 3Q24 with $281.0M in cash, cash equivalents, and marketable securities, which is slated to provide a runway into 2H26.
Research And DevelopmentThe initiation of the Phase 1 GALLOP trial for CB-010 by end-2024 is seen as a potential driver of future upside to forecasts.
Bears Say
Clinical TrialsPlanned pivotal trial for CB-010 is delayed by at least six months due to a focus on human leukocyte antigen matching.
Regulatory ApprovalThe probability of approval for CB-010 has been lowered to 20% from the prior 30% due to the decline in efficacy.
Stock Price TargetCB-010 results decline over time, prompting a reduction in the price target to $9.
---
Ownership Overview
7.99% Insiders
9.91% Mutual Funds
2.44% Other Institutional Investors
67.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.50 and its highest was $8.33 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $141.26M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Mar 24, 2025 which is in 65 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Nov 06, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.07.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.42.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 90,552,690 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went up 1.091%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
---
Caribou Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.43 (707.14% Upside)
$12.43 (707.14% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 113.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.61%
12-Months-Change
Fundamentals
Return on Equity
-43.60%
Trailing 12-Months
Asset Growth
-24.74%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
---
CRBU Stock 12 Month Forecast
Average Price Target
$12.43
▲(707.14% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Verve Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering CRBU
1 Year
1 Year Success Rate
2/24 ratings generated profit
1 Year Average Return
-38.90%
reiterated a buy rating 2 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -38.90% per trade.
---